NCT05257122Unknown2 期
A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Advanced Pancreatic Cancer Patients Who Failed Second-line Gemcitabine or 5-FU Based Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- progression free survival (PFS)
研究概览
简要总结
A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Advanced Pancreatic Cancer Patients Who Failed Second-line Gemcitabine or 5-FU Based Chemotherapy
详细描述
This study is an open Label, non-randomized, single-arm and multi-centered phase II clinical trial. It plans to evaluate the safety and efficacy of fruquintinib in advanced pancreatic cancer patients who failed second-line gemcitabine or 5-FU based chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-80 years old;
- •Locally advanced or recurrent/metastatic pancreatic adenocarcinoma confirmed by cytological or histopathological examination;
- •Have failed second-line chemotherapy (gemcitabine or 5-FU-based regiments) (the definition of treatment failure is: toxic and side effects are intolerable, disease progression during treatment, recurrence within six months after the end of adjuvant chemotherapy, or progression within three months after the end of palliative chemotherapy); prior chemotherapy are required to include gemcitabine or 5-FU or its derivatives;
- •With one or more measurable lesions, the longest diameter should be at least 10 mm measured by spiral CT scan, or at least 20 mm by conventional CT scan should be(RECIST standard, version 1.1);
- •ECOG score was 0-2;
- •Life expectancy ≥12 weeks;
- •The damage was recovered from other antitumor treatments, including the interval from nitroso or mitomycin to enrollment was ≥6 weeks, and the interval from other cytotoxic drugs, radiotherapy or surgery to enrollment was ≥4 weeks, and the wound was completely healed;
- •Acceptable hematologic, hepatic, and renal function within 7 days from screenin: absolute neutrophil count (ANC) ≥1.5x109 /L; Hemoglobin ≥ 9.0g/dL; Platelet count ≥80 x109 /L; Total bilirubin < 1.5 times upper limit of normal (ULN); ALT and AST< 2.5 x ULN (with liver metastasis <5x ULN); Serum creatinine ≤1 x ULN, endogenous creatinine clearance rate >50ml/min;
- •Women of reproductive age need to take effective contraceptive measures;
- •Participate in this study is voluntarily and sign informed consent. With good compliance to cooperate with the follow-up, participate should understand the purpose of this study and the necessary procedures.
排除标准
- •A history of other malignant tumors in the past 5 year: however, localized tumor cured in the study is excluded, including cervical carcinoma in situ and skin basal cell carcinoma.
- •Patients with hypertension that could not be controlled by antihypertensive drug therapy (systolic blood pressure >140mmHg, diastolic blood pressure >90mmHg), coronary heart disease of grade 1 or above, arrhythmia of grade 1 or above (including prolonged QTc interval > 450ms in males and > 470ms in females) and cardiac dysfunction of grade 1 or above;
- •Symptomatic brain or meningeal metastases (except those with stable brain metastases for more than one month after treatment);
- •Have a history of uncontrolled epileptic seizures, central nervous system dysfunction, or mental disorders;
- •Uncontrolled pleural or abdominal effusion;
- •Undergoing kidney dialysis;
- •Severe or uncontrolled infection;
- •With multiple factors affecting oral medication (inability to swallow, chronic diarrhea and intestinal obstruction);
- •Abnormal coagulation function (PT>16s, APTT>43s, TT>21s, Fbg< 2g/L), bleeding tendency, receiving thrombolytic or anticoagulant treatment, and a history of thrombosis or embolism within six months;
- •Patients at risk of gastrointestinal bleeding should not be enrolled, including: (1) patients with active digestive ulcer lesions and fecal occult blood (2+ or above); (2) patients with history of black stools and hematemesis within 3 months; (3) Patients with gastrointestinal fistula or perforation.
- •Participated in other medicine clinical trials within four weeks.
- •Weight less than 40kg.
- •Urine protein ≥2+ by urine routine
研究组 & 干预措施
Arm A
Experimental
Monotherapy of Fruquintinib
干预措施: Fruquintinib (Drug)
结局指标
主要结局
progression free survival (PFS)
时间窗: up to 24 months
The time from confirmation of enrollment to tumor progression or death from any cause, whichever came first
次要结局
- objective response rate (ORR)(through study completion, an average of 2 year)
- duration of response (DoR)(through study completion, an average of 2 year)
- overall survival (OS)(up to 36 months)
- disease control rate (DCR)(through study completion, an average of 2 year)
- safety: the potential side effects(through study completion, an average of 2 year)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT05636150Peking Union Medical College Hospital48
尚未招募
2 期
Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line ChemotherapyColorectal Cancer Stage IVColorectal CancerNCT05451719Fudan University116
进行中（未招募）
2 期
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic CancerMetastatic Pancreatic CancerPancreatic CancerNCT04820179University of Arizona32
进行中（未招募）
2 期
Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric CancerGastric CancerNCT05177068Henan Cancer Hospital42
Unknown
1 期
Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal CancerMetastatic Colorectal CancerNCT05016869Chinese Academy of Medical Sciences48